Woodline Partners’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
Woodline Partners's MLYS Position: Q3 2026 in Review
Woodline Partners opened a new position in Mineralys Therapeutics (MLYS) in Q3 2026: 969,389 shares worth $24.4M. The stake represents 0.07% of the portfolio and ranks #355 among its holdings. This is a return to the name: Woodline Partners previously reported a position in MLYS as recently as Q2 2025.
Woodline Partners first reported a position in MLYS in Q1 2023 and has held it in 7 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- Woodline Partners held 969,389 shares of Mineralys Therapeutics worth $24.4M as of Q3 2026.
- Mineralys Therapeutics was a new Woodline Partners position in Q3 2026.
- Mineralys Therapeutics made up 0.07% of Woodline Partners's portfolio in Q3 2026, its #355 holding.
- Woodline Partners first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 7 quarters since.
- 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.